Latest news with #Mone
Newsweek
5 days ago
- Entertainment
- Newsweek
Mercedes Mone Gives Savage Response To WWE Fans
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. AEW TBS Champion Mercedes Mone has a clear and savage message for any fans who are still hoping she will one day return to WWE. In a recent social media exchange, "The CEO" emphatically shut down the idea of a comeback. The interaction occurred on Mone's Instagram account. When a fan commented on one of her posts telling her to return to WWE, she did not hold back with her response. Mercedes Mone has made it clear that her focus is entirely on her career in All Elite Wrestling. She responded to the fan with a blunt and direct five-word message. "imma need your ugly ass to watch AEW," Mone wrote. This response reinforces the narrative that has defined her post-WWE career. She is a star who is determined to carve out her own path on her own terms. Before she was "The CEO" in AEW, Mercedes Mone was known to the world as Sasha Banks, one of the most decorated and influential female superstars in WWE history. As one of the "Four Horsewomen," she was a cornerstone of the Women's Revolution, helping to elevate women's wrestling to a main event level. SAN JOSE, CA - Oct. 16: AEW TBS Champion Mercedes Moné has her arms raised after defeating Queen Aminata on AEW Dynamite SAN JOSE, CA - Oct. 16: AEW TBS Champion Mercedes Moné has her arms raised after defeating Queen Aminata on AEW Dynamite Ricky Havlik/AEW More news: WWE Superstar Announces Retirement Match A multi-time champion and a Women's Grand Slam winner in WWE, her legendary feud with Bayley produced some of the most acclaimed matches in the company's history. However, her time with the company came to an abrupt and controversial end in May 2022. In May 2022, while they were the reigning WWE Women's Tag Team Champions, Mone and her partner Naomi walked out of an episode of Monday Night Raw due to creative frustrations. The move sent shockwaves through the industry and led to a long, contentious period where her future was uncertain. After leaving WWE, Mone proved she could be a major star on a global scale. She had a successful run in Japan, winning the prestigious IWGP Women's Championship. In March 2025, she made her highly anticipated debut for AEW at the Big Business special, where she won the TBS Championship in her first match. Mone has been a dominant champion ever since, and while she recently suffered her first singles loss to Toni Storm at All In, she remains a centerpiece of the AEW women's division. Her response to the fan makes it clear that she has no intention of looking back. More WWE News: For more on WWE, head to Newsweek Sports.
Business Journals
01-07-2025
- Business
- Business Journals
How Mark Mone's collaborative approach shaped UWM
Expand Chancellor Mone's Transformative Legacy event was held at the UWM Lubar Entrepreneurship and UWM Welcome Center. KENNY YOO/MBJ 1 of 20
Time of India
27-06-2025
- Business
- Time of India
Torrent Pharma closes in on JB Chem likely for $2.4 bn buyout, eyes $1.6 billion financing
Torrent Pharma is in advanced discussions with private equity group KKR to buy JB Chemicals and Pharmaceuticals, almost 10 months after their initial discussions fell through, said multiple people aware. KKR the controlling shareholder owns 47.84% of the company via its investment vehicle TAU Investment. The transaction will include buying out KKR from its 5 year old investment. In July 2020, KKR acquired around 54 percent of JB Pharma from its promoters and founders, the Mody family, for approximately Rs 3,100 crore translating to Rs 745 per share. It will also trigger an open offer for an additional 26% of the company. If fully successful, Torrent could end up owning 73.84 per cent of the company. At current price, that could lead to a Rs 20,734.61 crore buyout for Torrent – its largest so far. Acquisition of KKR's stake alone would translate to a Rs 13,433.69 crore transaction. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Punjab Mosquito-Free Nights: Residents Share Unexpected Secret Mosquito Eliminator Read More Undo A formal announcement is expected in coming weeks, one of the sources mentioned above added. JB Chemicals closed Friday at Rs 1799.35/share, up 3% from the previous day's closing. Its current market value is Rs 28,080.46 crore. The JB Chemical stock had touched a 52-week high on 16th August 2024, and has dropped 4.58% year to date. Live Events JB Pharma has been a turnaround story backed by a string of deals and a push to some of its own brands like Nicardia (hypertension), Rantac (antiulcer), Cilacar and Metrogyl (antibacterial). For Torrent, these hit brands will come handy in the hyper competitive branded generic market in India, more so because these products have a strong reputation with the doctors. Of the total sales of roughly Rs 3900 crore, JB leading eight brands account for half. Additionally, Torrent will make an entry into the CDMO business via JB Pharma's high quality alliances with multinational companies for cough lozenges. Torrent, Alkem and EQT were in separate negotiations with KKR last year, when the US buyout fund had launched a formal sale process but that failed due to valuation mismatch. The talks are believed to have resumed bilaterally in recent weeks. KKR declined to comment. Mails sent to Torrent Pharma did not generate a response till press time. Ahmedabad headquartered Torrent is also holding financing negotiations with HSBC, Standard Chartered Bnak and Barclays to arrange $1.6 billion rupee financing. The three were the financing banks last year as well, so they have sought 'refreshed approvals on the bond structure.' The INR bond facility is being raised to fund the equity requirement for the transaction and is likely to be backed by promoter group entities or select downstream cash flows,' one of the people said. Mails to HSBC remained unanswered as of press time Friday, while Standard Chartered and Barclays spokesperson declined to comment. Moneycontrol was the 1st to report that Torrent has revived its JB Chemicals buyout plans on Friday evening. Earlier this March, KKR sold a little above 5% stake in the open market via a block deal and raised Rs 1459 crore. 'Unlike Max Healthcare, where KKR sold significant chunks of the company, in JB Chemicals selling close to 50% would have been difficult. Torrent has always been keen but last time there was a difference in price expectations and the stock had significantly run up,' said an industry executive on condition of anonymity. In 2023, Torrent was aggressively pursuing a $7 billion buyout of Cipla that got aborted following differences within the promoter family. It also made a billion dollar play to take over Biogaran, France's largest generics company, from Servier last year, before the French government intervened to block the divestment. Torrent's current market capitalisation is Rs 1,13,184.61 crore with the promoters, the Mehta family, owning 68.21% of the company. TURNAROUND STORY Under CEO Nikhil Chopra, who was brought in by KKR from Cipla, JB Pharma has seen a significant ramp up in its sales and profitability. For the financial year 2024-25, JB Pharma recorded a revenue of Rs 3,918 crore compared to Rs 3,484 crore in FY23-24, registering 12 percent growth. JB Pharma has also aligned with Novartis to sell its new generation cardiovascular drug Izirize (inclisiran), demonstrating its deeper and innovative drugs presence in the cardiology market. In a recent interview with ET, Torrent Pharma MD designate Aman Mehta told ET recently that he is aiming to be in the top three slot in the Indian market in three to five years. "As far as the India market is concerned, we have reached the position today through mainly inorganic growth over the last decade." He added 'Our rank was much lower 10 years ago than it is today. That's certainly a big positive that has happened in the sense that from where we were to where we are, we are in a much stronger position to invest further and even grow the business from here.' While hinting at big buyouts, Mehta said, "I would say that from here onwards, acquisitions will continue to remain a priority. And the top three in the Indian market is something that we have our eyes on. Organically it may be difficult to achieve in the near term. But certainly through inorganic growth it seems quite possible, and may be in the next couple of years, if something materializes, that certainly is going to be part of our ambition."
Daily Mirror
13-06-2025
- Business
- Daily Mirror
Michelle Mone told it would be 'disappointing' if PPE firm made little profit
The Department for Health and Social Care is suing PPE Medpro for £130m after Baroness Mone acted as an introducer, saying the gowns were not sterile and unfit for use - the company denies the claims Conservative peer Baroness Michelle Mone was told by a boss of a PPE firm that it would be disappointing if the company made little or no profit, the High Court heard. Her husband Doug Barrowman was at the court yesterday for the second day of a £130million trial over PPE Medpro, a company he backed. The Department of Health and Social Care is seeking the return of £122m it spent on surgical gowns bought during the pandemic along with £8.6m in storage and transportation costs. The High Court heard that the gowns were not sterile and unusable in the NHS when delivered in 2020. PPE Medpro said it "categorically denies" breaching the contract, and its lawyers claimed it has been "singled out for unfair treatment". The company was backed by a consortium led by Mr Barrowman and the initial contact with the government's PPE team came from Baroness Mone. Written submissions in the case state that Baroness Mone was told by firm boss Anthony Page that it would be "extremely disappointing" if it made little or no profit. A few days before the contract was signed for 25 million gowns, fewer than the 50 million originally proposed, Mr Page wrote to her, saying: "Tomorrow we will submit our best price. As I said our margin will be tiny or possibly nothing at all as we have bought all the production capacity upfront. We really need to achieve a positive outcome to this extremely disappointing situation." Opening the trial on Wednesday, Paul Stanley KC, for the DHSC, said: "This case is simply about whether 25 million surgical gowns provided by PPE Medpro were faulty." Mr Stanley said 99.9999% of the gowns should have been sterile under the terms of the contract - equating to one in a million being unusable. 140 gowns were later tested for sterility, with 103 failing, and he added: "Whatever was done to sterilise the gowns had not achieved its purpose, because more than one in a million of them was contaminated when delivered. Mr Stanley said that the gowns were 'unusable in the NHS or any other setting', adding: 'Without the relevant assurances of conformity that the gowns met sterility requirements, the potential impact on safety was such that they could seriously harm or kill patients and so could not be released for use.' In his written submissions, Charles Samek KC, for PPE Medpro, said the "only plausible reason" for the gowns becoming contaminated was due to "the transport and storage conditions or events the gowns were subject", after they had been delivered. He added the testing did not happen until several months after the gowns were rejected, and the samples selected were not "representative of the whole population", meaning "no proper conclusions may be drawn". He said the DHSC's claim was "contrived and opportunistic" and PPE Medpro had been "made the 'fall guy' for a catalogue of failures and errors" by the department. He said: "It has perhaps been singled out because of the high profiles of those said to be associated with PPE Medpro, and/or because it is perceived to be a supplier with financial resources behind it. "In reality, an archetypal case of 'buyer's remorse', where DHSC simply seeks to get out of a bargain it wished it never entered into, left, as it is, with over £8 billion of purchased and unused PPE as a result of an untrammelled and uncontrolled buying spree with taxpayers' money." Bra tycoon Baroness Mone, 53, and Isle of Manbased entrepreneur Mr Barrowman, 60, who wed in 2020, both deny wrongdoing. They are facing a separate National Crime Agency investigation into PPE Medpro. A PPE Medpro spokesman said it "categorically denies breaching its obligations" and will "robustly defend" the claim. The trial is due to last five weeks, with a judgment expected at a later date.
Scottish Sun
11-06-2025
- Business
- Scottish Sun
Firm linked to bra tycoon Michelle Mone begins court battle over dodgy Covid kit
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A FIRM linked to bra tycoon Michelle Mone has begun a court battle to keep £122million it received for dodgy Covid protection kit. UK health chiefs are suing PPE Medpro — which Baroness Mone, 53, and her husband Doug Barrowman, 60, both from Glasgow, had denied for years they were involved with 3 A firm linked to bra tycoon Michelle Mone will appear in court Credit: Corbis 3 The bra tycoon and husband Doug Barrowman Credit: Getty 3 Michelle Mone ahead of the State Opening of Parliament Credit: PA The High Court in London was told 25million surgical gowns had been rejected as unsuitable for the NHS as it was deemed 'non-sterile' with 'invalid technical labelling'. It was later revealed that Baroness Mone had lobbied Tory ministers on behalf of the consortium. Both deny wrongdoing, as do Medpro over gowns supplied in 2020. Paul Stanley KC, for the Department of Health and Social Care, said 'initial contact with the firm came through Baroness Mone' and she remained 'active throughout'. But he added her communications were 'not part of this case', which was 'about compliance'. PPE Medpro won two contracts worth over £200million via the UK Government's 'VIP lane' procurement process. TELLY HOST'S SHOCK By Matt Bendoris BBC host Laura Kuenssberg has revealed the interview that 'sticks' with her the most is when Michelle Mone confessed to being a liar. Scots bra tycoon Mone spent two years fiercely denying through an army of lawyers any involvement with the firm PPE Medro, which had earned over £200million worth of Government contracts to supply face masks and surgical gowns during the Covid pandemic. But in 2023 it was revealed that the Tory life peer and her three adult children had received £29million from the company via her second husband Doug Barrowman. That led to a 'Prince Andrew-style' TV showdown with the politics presenter on her weekly show Sunday with Laura Kuenssberg. Appearing alongside Barrowman, 60, Baroness Mone, 53, made the jaw-dropping confession: 'I can't see what we've done wrong. Lying to the press is not a crime.' Read more HERE It was later revealed Mr Barrowman had received more than £65million in profits from the contracts. And he confirmed he transferred £29million from the firm into a trust benefiting Baroness Mone and her three children. Neither the Tory peer nor her husband are expected to give evidence during the trial. The UK Government is seeking to recover the costs of the contract plus transport and storage expenses. Trial continues. Carol Vorderman reignites feud with ex-pal Michelle Mone in furious rant on This Morning Meanwhile Mone's ex-lawyer has denied telling her to lie about links to a scandal-hit firm. Jonathan Coad insisted the Scots bra tycoon's allegation that he did was 'not true'. Baroness Mone, 53, blamed him for her three-year refusal to confirm her connection to PPE Medpro — given £200million for Covid protection kit and now being probed by cops. Mr Coad, 67, said: 'I did not advise her she should keep her involvement secret. "The suggestion she did so by taking the advice of her lawyers is just not true. "To have Baroness Mone make allegations against me of serious impropriety was potentially very damaging."
